The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

被引:27
作者
Schmitz, Susanne [1 ]
Maguire, Aine [2 ,3 ]
Morris, James [4 ]
Ruggeri, Kai [3 ,14 ]
Haller, Elisa [5 ]
Kuhn, Isla [6 ]
Leahy, Joy [7 ]
Homer, Natalia [4 ]
Khan, Ayesha [8 ]
Bowden, Jack [9 ]
Buchanan, Vanessa [4 ]
O'Dwyer, Michael [10 ]
Cook, Gordon [11 ,12 ]
Walsh, Cathal [13 ]
机构
[1] Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, Luxembourg
[2] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland
[3] Univ Cambridge, Dept Psychol, Cambridge, England
[4] Cogentia Healthcare Consulting, Cambridge, England
[5] Univ Zurich, Dept Psychol, Zurich, Switzerland
[6] Univ Cambridge, Univ Lib Med Lib, Cambridge, England
[7] Trinity Coll Dublin, Dept Comp Sci & Stat, Dublin, Ireland
[8] Univ Exeter, Exeter, Devon, England
[9] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England
[10] NUI Galway, Dept Med, Galway, Ireland
[11] St James Univ Hosp, Haematol & Myeloma Studies, Leeds, W Yorkshire, England
[12] St James Univ Hosp, NIHR MIC DEL, Leeds, W Yorkshire, England
[13] Univ Limerick, Hlth Res Inst, Limerick, Ireland
[14] Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY USA
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2018年 / 18卷
关键词
Network meta-analysis; Single armed studies; Evidence synthesis; Relapsed or refractory myeloma; LENALIDOMIDE PLUS DEXAMETHASONE; ADJUSTED INDIRECT COMPARISONS; MIXED TREATMENT COMPARISONS; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; PROPENSITY SCORE; REFRACTORY MYELOMA; TREATMENT OUTCOMES; BORTEZOMIB; THERAPY;
D O I
10.1186/s12874-018-0509-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Network meta-analysis (NMA) allows for the estimation of comparative effectiveness of treatments that have not been studied in head-to-head trials; however, relative treatment effects for all interventions can only be derived where available evidence forms a connected network. Head-to-head evidence is limited in many disease areas, regularly resulting in disconnected evidence structures where a large number of treatments are available. This is also the case in the evidence of treatments for relapsed or refractory multiple myeloma. Methods: Randomised controlled trials (RCTs) identified in a systematic literature review form two disconnected evidence networks. Standard Bayesian NMA models are fitted to obtain estimates of relative effects within each network. Observational evidence was identified to fill the evidence gap. Single armed trials are matched to act as each other's control group based on a distance metric derived from covariate information. Uncertainty resulting from including this evidence is incorporated by analysing the space of possible matches. Results: Twenty five randomised controlled trials form two disconnected evidence networks; 12 single armed observational studies are considered for bridging between the networks. Five matches are selected to bridge between the networks. While significant variation in the ranking is observed, daratumumab in combination with dexamethasone and either lenalidomide or bortezomib, as well as triple therapy of carfilzomib, ixazomib and elozumatab, in combination with lenalidomide and dexamethasone, show the highest effects on progression free survival, on average. Conclusions: The analysis shows how observational data can be used to fill gaps in the existing networks of RCT evidence; allowing for the indirect comparison of a large number of treatments, which could not be compared otherwise. Additional uncertainty is accounted for by scenario analyses reducing the risk of over confidence in interpretation of results.
引用
收藏
页数:18
相关论文
共 50 条
[21]   A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis [J].
Dimopoulos, Meletios Athanasios ;
Kaufman, Jonathan L. ;
White, Darrell ;
Cook, Gordon ;
Rizzo, Maria ;
Xu, Yingxin ;
Fahrbach, Kyle ;
Gaudig, Maren ;
Slavcev, Mary ;
Dearden, Lindsay ;
Lam, Annette .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (03) :163-+
[22]   Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma [J].
Dolph, Michael ;
Tremblay, Gabriel ;
Gilligan, Adrienne M. ;
Leong, Hoyee .
JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2021, 8 (02) :26-35
[23]   Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens [J].
Botta, Cirino ;
Martino, Enrica Antonia ;
Conticello, Concetta ;
Mendicino, Francesco ;
Vigna, Ernesto ;
Romano, Alessandra ;
Palumbo, Giuseppe Antonio ;
Cerchione, Claudio ;
Martinelli, Giovanni ;
Morabito, Fortunato ;
Di Raimondo, Francesco ;
Gentile, Massimo .
FRONTIERS IN ONCOLOGY, 2021, 11
[24]   Efficacy of Carfilzomib in the Treatment of Relapsed and (or) Refractory Multiple Myeloma: a Meta-analysis of Data from Clinical Trials [J].
Chen, Runzhe ;
Chen, Baoan ;
Zhang, Xiaoping ;
Gao, Chong .
DISCOVERY MEDICINE, 2016, 22 (121) :189-199
[25]   Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome [J].
Van Beurden-Tan, Chrissy H. Y. ;
Sonneveld, Pieter ;
Uyl-de Groot, Carin A. .
BMC CANCER, 2022, 22 (01)
[26]   Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma [J].
DerSarkissian, Maral ;
Cranmer, Holly ;
Dabora, Jonathan ;
Bocharova, Iryna ;
Cherepanov, Dasha ;
Cheng, Mu ;
Bhak, Rachel H. ;
Duh, Mei Sheng .
HEMATOLOGY, 2023, 28 (01)
[27]   Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis [J].
Xu, Wenjun ;
Li, DianFang ;
Sun, Yanhua ;
Ran, Xuehong ;
Wang, Baohong ;
Wu, Wei ;
Sheng, Zhixin ;
Liu, Liping .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (06) :542-551
[28]   A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation [J].
Weisela, Katja ;
Doyen, Chantal ;
Dimopoulos, Meletios ;
Yee, Adrian ;
Jose Lahuerta, Juan ;
Martin, Amber ;
Travers, Karin ;
Druyts, Eric ;
Toor, Kabirraaj ;
Abildgaard, Niels ;
Lu, Jin ;
Van Droogenbroeck, Jan ;
Geraldes, Catarina ;
Petrini, Mario ;
Voillat, Laurent ;
Voog, Eric ;
Facon, Thierry .
LEUKEMIA & LYMPHOMA, 2017, 58 (01) :153-161
[29]   Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials [J].
Singh, Janharpreet ;
Gsteiger, Sandro ;
Wheaton, Lorna ;
Riley, Richard D. ;
Abrams, Keith R. ;
Gillies, Clare L. ;
Bujkiewicz, Sylwia .
BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
[30]   A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma [J].
Mohyuddin, Ghulam Rehman ;
Hampton, Jill ;
Aziz, Muhammad ;
Khuder, Sadik ;
Malik, Saad ;
McClune, Brian ;
Abdallah, Al-Ola .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (07) :489-496